🧬 BioMed Pulse · 2026-07-17 02:01 UTC

BIOMED PULSE

July 17, 2026 | Daily Briefing on Longevity, Viruses & New Cures

⚡ TL;DR

The Ebola Bundibugyo virus outbreak in DRC and Uganda has now surpassed 1,460 confirmed cases and 452 deaths as of July 1, making it the dominant global health emergency of 2026. Mood: urgent on multiple fronts — Ebola, West Nile, and a fresh Salmonella outbreak all broke overnight.

🦠 OUTBREAKS & VIRUSES

EBOLA BUNDIBUGYO VIRUS - DRC AND UGANDA (PHEIC)

• As of July 1, 2026, the DRC reported 1,460 confirmed Bundibugyo virus disease (BVD) cases and 452 confirmed deaths; cross-border transmission into Uganda continues. ^[1]
• WHO's July 10 statement confirms the outbreak remains active; WHO declared BVD a Public Health Emergency of International Concern (PHEIC) on May 22. ^[2][3]
• The WHO-sponsored PARTNERS clinical trial opened patient enrollment in DRC on July 2 to evaluate the first candidate treatments specifically for Bundibugyo virus disease. ^[4]
• WHO added the first molecular diagnostic test for Bundibugyo virus (BDBV) to its Emergency Use Listing on July 2, enabling rapid genetic detection from blood samples. ^[5]
• Africa CDC and WHO launched a joint continental Ebola response plan on June 5 seeking to raise US$518 million to support African countries' preparedness. ^[6]
• WHO issued its first comprehensive clinical management guidelines for all filovirus diseases — including all Ebola species and Marburg virus — on June 17. ^[7]
• CDC mobilized international response and activated enhanced Ebola airport screening at Washington-Dulles and Atlanta airports in May; screening remains in effect. ^[8][9]

ANDES HANTAVIRUS - M/V HONDIUS CRUISE SHIP (MULTI-COUNTRY)

• The fifth WHO Disease Outbreak News update posted July 2 confirms the Andes hantavirus (ANDV) cluster remains linked to the M/V Hondius cruise ship, which first reported severe respiratory illness cases on May 2. ^[10]
• A June 24 CDC transcript indicates ongoing monitoring of the multi-country hantavirus response.

NIPAH VIRUS - INDIA (KERALA)

• On June 11, Kerala State confirmed a laboratory case of Nipah virus (NiV) in Kozhikode district: an adult male with neurological symptoms hospitalized June 10; contact tracing is underway.
• Earlier in 2026, two healthcare workers at a Barasat hospital in West Bengal and one case in Bangladesh's Rajshahi Division were also confirmed NiV-positive.

WEST NILE VIRUS - UNITED STATES

• CDC issued a July 1 alert warning of a record early West Nile season with higher-than-usual case counts, urging mosquito bite prevention during the July 4th holiday period and beyond.

SALMONELLA - FROZEN SPROUTED BEANS (NEW, JULY 17)

• CDC posted a new alert today: 11 people in 10 states are sick with the same Salmonella strain linked to frozen sprouted beans.

MPOX - RECOMBINANT STRAIN (GLOBAL)

• WHO reported in February 2026 two confirmed cases of a recombinant monkeypox virus combining clade Ib and IIb genomic elements, a recognized but closely watched natural recombination event.

AVIAN INFLUENZA A(H9N2) - ITALY

• Italy reported one human case of avian influenza A(H9N2) in an adult male returning from Senegal; confirmed by next-generation sequencing in March 2026.

MEASLES - BANGLADESH

• As of April 2026, Bangladesh reported 19,161 suspected measles cases across 58 of 64 districts, with 2,897 laboratory-confirmed; WHO issued a formal Disease Outbreak News notification.

YELLOW FEVER - GLOBAL

• From January 1 to May 26, 2026, six countries reported 79 human yellow fever infections; elevated transmission in the Americas that began in 2025 continued into 2026.

CANCER PROJECTIONS - WHO

• WHO issued a July 8 report projecting new global cancer cases will nearly double by 2050, from an estimated 20.6 million new cases and close to 10 million deaths annually today.

🧬 LONGEVITY & AGING

NAD-PLUS HOMEOSTASIS AND BONE REPAIR IN AGING

• A study published in Bioactive Materials (Jiang et al., June 27, 2026) reports a senescent metabolism-modulating hierarchical scaffold that restores NAD-plus homeostasis and redox balance, improving aged bone repair in experimental models.
• NAD-plus depletion is a hallmark of cellular senescence; restoring it in aged tissue is a central geroscience target, and this scaffold approach offers a localized delivery mechanism.

DELIRIUM AS A MISSING LINK - INFECTION, DELIRIUM, DEMENTIA

• Two Lancet Healthy Longevity analyses (Sipilä, Kivimäki; Penfold, Jiwaji, MacLullich et al.) propose that delirium following severe infection may be a key mechanistic bridge to subsequent dementia development in older adults.
• The authors argue delirium is under-recognized and under-treated and call for it to be treated as a dementia-risk event requiring formal follow-up.

DEMENTIA PREVENTION - PREPARING FOR THE ERA

• A Lancet Healthy Longevity commentary by Beeri and Gu argues the world must now prepare practical dementia prevention strategies for diverse real-world populations, not just controlled trial settings.

TAU PATHOLOGY AND NUCLEAR MECHANOTRANSDUCTION IN NEURONS

• Research published in Nucleus (Sohn et al., July 7, 2026) shows the mechanically-sensitive nuclear protein emerin is elevated in neurons undergoing tau-induced cytoskeletal remodeling, linking nuclear mechanotransduction to tau pathology relevant to Alzheimer's disease and other tauopathies.

KAEMPFEROL FROM MORINGA AND LONGEVITY IN DROSOPHILA

• A Toxicology Reports study (Iorjiim et al., June 25, 2026) found kaempferol extracted from Moringa oleifera increased lifespan and ameliorated efavirenz-induced functional senescence in Drosophila melanogaster, suggesting a potential antisenescence mechanism.

HYPERTENSION AND FRAILTY IN OLDER ADULTS - INDIA

• A letter in Blood Pressure (Goyal, Kalra, Nagpal, July 7, 2026) raises concerns about the relationship between hypertension and frailty in middle-aged and older adults using data from the Longitudinal Ageing Study in India.

TOBACCO-LINKED LIVER DISEASE BURDEN

• A Journal of Diabetes and Metabolic Disorders study (Xu et al., July 3, 2026) analyzed the global burden of metabolic dysfunction-associated steatotic liver disease (MASLD) attributable to tobacco from 1990 to 2023 and projected trends to 2038.

PHYSICAL ACTIVITY RESTRICTION AND CEREBROVASCULAR MORTALITY - JAPAN

• An ecological panel study across 47 Japanese prefectures (2013-2022) by Kimura found structural physical activity restriction was linked to cerebrovascular and diabetes mortality and increased long-term care intensity, with a COVID-19 counterfactual analysis.

SOCIAL DETERMINANTS OF HEALTHY LONGEVITY

• A Russian-language analysis (Amonova et al., Problemy Sotsialnoi Gigieny) identifies medical and social determinants of healthy longevity including prevention strategies, framing longevity as a system-level challenge rather than individual behavior.

💊 NEW CURES & APPROVALS

LEQEMBI IQLIK (LECANEMAB-IRMB) - EISAI INC - SUPPLEMENTAL APPROVAL

• Eisai's lecanemab-irmb (brand: LEQEMBI IQLIK, BLA 761375) received a supplemental FDA approval action; lecanemab is an anti-amyloid monoclonal antibody indicated for early Alzheimer's disease.

VERZENIO (ABEMACICLIB) - ELI LILLY - SUPPLEMENTAL APPROVAL

• Eli Lilly's abemaciclib (brand: VERZENIO, NDA 208716) received a supplemental FDA approval; abemaciclib is a CDK4/6 inhibitor used in hormone receptor-positive, HER2-negative breast cancer.

RINVOQ LQ (UPADACITINIB) - ABBVIE - SUPPLEMENTAL APPROVAL

• AbbVie's upadacitinib liquid formulation (brand: RINVOQ LQ, NDA 218347) received a supplemental FDA approval; upadacitinib is a JAK1 inhibitor indicated for multiple inflammatory conditions including rheumatoid arthritis and atopic dermatitis.

RILPIVIRINE HYDROCHLORIDE - LAURUS - ORIGINAL APPROVAL

• Laurus received an original FDA approval (ANDA 219788) for a generic rilpivirine hydrochloride tablet; rilpivirine is a non-nucleoside reverse transcriptase inhibitor used in HIV-1 treatment.

GLEEVEC (IMATINIB MESYLATE) - NOVARTIS - SUPPLEMENTAL APPROVAL

• Novartis received a supplemental FDA approval for imatinib mesylate (brand: GLEEVEC, NDA 021588); imatinib is a BCR-ABL tyrosine kinase inhibitor used in chronic myeloid leukemia and other malignancies.

🧪 CLINICAL TRIALS

LOCUS COERULEUS AND COGNITIVE AGING - NCT06058897

• A trial registered July 16, 2026, is recruiting cognitively healthy adults over 60 to investigate MRI and eye-tracking markers of locus coeruleus (LC) neuronal integrity; the LC is the brain's sole noradrenaline source and shows tau pathology among the earliest in Alzheimer's disease.

PET IMAGING OF NORADRENERGIC TRANSMISSION - NCT07686393

• A new NIH-registered trial (July 16, 2026) is testing the PET radiotracer 11C-ARMI to image noradrenergic neurotransmission in the brain, with potential applications in Alzheimer's disease and other neurodegeneration conditions.

DENGUE AND CHIKUNGUNYA VACCINE CO-ADMINISTRATION - NCT06973772

• A randomized, double-blind, controlled trial (registered July 16, 2026) in adults aged 18-59 is assessing the safety and immunogenicity of co-administering live attenuated dengue and chikungunya vaccines versus separate administration, targeting populations with no prior exposure.

VAS-101 (CURCUMIN FORMULATION) IN SICKLE CELL DISEASE - NCT07566494

• A new trial (registered July 16, 2026) is testing escalating doses of VAS-101, a bioavailable curcumin formulation, in patients with stable sickle cell disease; curcumin has been shown to improve red blood cell health in preclinical SCD models but suffers from poor natural bioavailability.

HIGH-DENSITY THETA BURST STIMULATION (HDTBS) - NCT06868914

• A Phase I trial registered July 16, 2026 is evaluating a new form of transcranial magnetic stimulation called high-density TBS (hdTBS), building on standard theta burst stimulation which is already FDA-approved for major depression.

📢 PUBLIC HEALTH

DRUG-RESISTANT BACTERIA SHARP RISE - CDC REPORT

• A CDC report released September 23, 2025 found a dramatic increase in dangerous drug-resistant bacteria in U.S. healthcare settings; a new July 15, 2026 CDC data release confirms continued improvement in overall healthcare-associated infection rates in 2023 despite the AMR rise.

HEALTHCARE-ASSOCIATED INFECTIONS DECLINING - CDC 2026

• CDC data published July 15, 2026 show a decline in hospital-acquired infections in 2023, highlighting improved patient safety practices across U.S. facilities.

TRACHOMA ELIMINATION - EL SALVADOR

• WHO validated El Salvador on July 13, 2026 as having eliminated trachoma as a public health problem; trachoma is the world's leading infectious cause of blindness.

TICK BITES - HIGHER-THAN-USUAL ER VISITS THIS SEASON

• CDC data released April 23, 2026 show weekly emergency room visits for tick bites are running higher than usual for the season; the CDC is urging protective measures during outdoor activity.

E. COLI - FROZEN BLUEBERRIES

• CDC issued a food safety alert July 7, 2026 warning consumers not to eat recalled frozen blueberries linked to an E. coli outbreak.

INFANT BOTULISM - NARA ORGANICS FORMULA

• CDC updated its June 13, 2026 alert urging parents to immediately stop using all Nara Organics Whole Milk Organic Infant Formula linked to a botulism cluster.

LISTERIA - REQUESÓN AND SOFT RICOTTA CHEESE

• CDC issued a Listeria outbreak warning June 5, 2026 linked to requesón and soft ricotta cheese; consumers should check for recalled products.

UNSAFE FOOD - WHO GLOBAL BURDEN ESTIMATE

• WHO reported June 3, 2026 that unsafe food causes 866 million illnesses and 1.5 million deaths annually worldwide; children under five face nearly three times the risk compared to older individuals.

This briefing is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personal health decisions.

📎 Sources

1. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
2. CDC Statement on Ebola Outbreak in the Democratic Republic of … — CDC Newsroom
3. First meeting of the IHR Emergency Committee regarding the epi… — WHO News
4. Patient enrolment begins in a scientific trial to identify the… — WHO News
5. WHO adds first diagnostic test for Ebola Bundibugyo virus to i… — WHO News
6. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
7. WHO issues comprehensive guidelines on filovirus disease, incl… — WHO News
8. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
9. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
10. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260717-02-v30 · 2026-07-17 02:01 UTC · pulse.uzylab.com